These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 561037)

  • 1. Antipsychotic effects, side effects and effective dosis of the butyrophenone lenperone (AHR 2277).
    Woggon B; Franke A; Hucker H; Ruether E; Athen D; Angst J; Hippius H
    Int Pharmacopsychiatry; 1977; 12(2):113-26. PubMed ID: 561037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early clinical trial of lenperone (AHR 2277), a butyrophenone, in chronic schizophrenia.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1974 May; 16(5):477-82. PubMed ID: 4209063
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary evaluation of a new psychotropic drug, lenperone, in the treatment of acute schizophrenia.
    Nakra BR; Jones CJ; Majumdar AK; Gaind R
    Curr Med Res Opin; 1977; 4(8):529-34. PubMed ID: 559569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute schizophrenia with a new butyrophenone-lenperone.
    Harris M
    J Clin Pharmacol; 1975; 15(2-3):187-90. PubMed ID: 1091666
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot open-label study of lenperone (AHR 2277), a butyrophenone, in anxiety.
    Fabre LF; Harris RT
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):328-31. PubMed ID: 817861
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of antipsychotic activity of a butyrophenone analogue, lenperone (AHR 2277).
    Sathanathan GL; Angrist BM; Phillips N; Gershon S
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):844-7. PubMed ID: 4217252
    [No Abstract]   [Full Text] [Related]  

  • 7. Lenperone: a controlled evaluation in chronic schizophrenic patients.
    Mielke DH; Gallant DM; Kessler C; Roniger JJ
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):636-40. PubMed ID: 812640
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of diagnosis, hospital and sex on the effects of bromperidol].
    Woggon B; Fleischhauer J; Widmer A
    Int Pharmacopsychiatry; 1979; 14(4):213-27. PubMed ID: 42629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
    Sumiyoshi T; Jayathilake K; Meltzer HY
    Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of bromperidol and perphenazine.
    Woggon B; Angst J
    Int Pharmacopsychiatry; 1978; 13(3):165-76. PubMed ID: 355182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison of AL-1021 and chlorpromazine in hospitalized schizophrenics.
    Gendron JL; Zimmermann RL; Schiele BC
    Curr Ther Res Clin Exp; 1973 Jun; 15(6):333-6. PubMed ID: 4197258
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
    Kariya T; Shimazono Y; Itoh H; Mori A; Murasaki M; Sugano K; Toru M; Yamashita I
    J Int Med Res; 1983; 11(2):66-77. PubMed ID: 6133803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
    Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
    J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Penfluridol. Results of a year-long clinical trial].
    Woggon B
    Int Pharmacopsychiatry; 1978; 13(1):1-15. PubMed ID: 342435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
    Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.